PharmaCielo Ltd. announced that it has delivered its first commercial shipment of medicinal grade CBD isolate (the "Initial Shipment") to a well-established, bulk distributor and white label manufacturer based in the U.K., with sales and distribution operations in the U.K., and the E.U. (the "Customer"). In addition, the Company has reached an interim sales agreement with the Customer, lasting until the end of Q1-2021, at which point PharmaCielo expects to have submitted a Novel Foods authorization application for its range of CBD extracts. The interim, renewable agreement enables continued shipments for the remainder of 2020 and calls for the shipment of up to 1,000 kg of CBD Isolate and Broad-Spectrum CBD based on the Customer's specifications, during Q1-2021. With submission of the Novel Foods authorization application prior to March 31, the Company expects to be in a position to subsequently expand both volume and exported consumable product types during fiscal 2021 in accordance with regulatory requirements. In addition, the Company has reached an interim sales agreement with the Customer, lasting until the end of Q1-2021, at which point PharmaCielo expects to have submitted a Novel Foods authorization application for its range of CBD extracts. The interim, renewable agreement enables continued shipments for the remainder of 2020 and calls for the shipment of up to 1,000 kg of CBD Isolate and Broad-Spectrum CBD based on the Customer's specifications, during Q1-2021. With submission of the Novel Foods authorization application prior to March 31, the Company expects to be in a position to subsequently expand both volume and exported consumable product types during fiscal 2021 in accordance with regulatory requirements.